GlaxoSmithKline PLC (GSK)
27 Oct 2016
LONDON, Oct 26 GlaxoSmithKline comments on China during third-quarter results:
LONDON GlaxoSmithKline beat quarterly sales and profit expectations and said it expected even bigger gains in 2016 thanks to a weak pound, which has continued to fall after Britain's vote in June to leave the European Union.
* Q3 revenue 7.54 bln pounds vs consensus 7.28 bln (Adds CEO comment on UK prices, analyst reaction, product details)
Oct 26 GlaxoSmithKline CEO Andrew Witty told reporters:
LONDON, Oct 26 Drugmaker GlaxoSmithKline said on Wednesday it expected even bigger profit gains in 2016 thanks to a weak pound, which has continued to fall after Britain's vote in June to leave the European Union, as quarterly results beat expectations.
* Fimbrion - co and GSK to develop novel antibacterial therapy for urinary tract infections Source text for Eikon: Further company coverage:
LONDON GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market.
* Consensus forecasts point to $1.05 billion sales in 2021 (Adds sales forecast, background on rival vaccines)
LONDON, Oct 24 GlaxoSmithKline said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market.
* Announces U.S. regulatory submission of candidate vaccine for prevention of Shingles
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,788||-16.00|
|Procter & Gamble Co (PG.N)||$86.79||-0.61|
|Johnson & Johnson (JNJ.N)||$115.94||+1.38|
|Pfizer Inc. (PFE.N)||$32.59||+0.19|
|Novartis AG (NOVN.S)||CHF71.40||+0.20|
|Unilever N.V. (UNc.AS)||€38.33||-0.16|
|Unilever N.V. (UNIA.AS)||€38.51||+0.17|
|Unilever N.V. (UN_pa.AS)||€989.00||--|
|Unilever N.V. (UN_p.AS)||€92.00||+7.99|
|Unilever N.V. (UN_pb.AS)||--||--|